Mobile Health App for Japanese Adult Patients With Asthma: Clinical Observational Study.
ResearchKit
asthma
cough variant asthma
mobile health
Journal
Journal of medical Internet research
ISSN: 1438-8871
Titre abrégé: J Med Internet Res
Pays: Canada
ID NLM: 100959882
Informations de publication
Date de publication:
14 08 2020
14 08 2020
Historique:
received:
31
03
2020
accepted:
14
05
2020
revised:
05
05
2020
entrez:
16
8
2020
pubmed:
17
8
2020
medline:
26
1
2021
Statut:
epublish
Résumé
Inappropriate asthma control reduces quality of life and causes increased exacerbations. Mobile health (mHealth) employs information and communication technology for surveying health-related issues. This noninterventional, observational study assessed current real-world asthma control levels among Japanese patients with asthma and cough variant asthma (CVA) using the Zensoku-Log app. We developed the app using the ResearchKit platform and conducted a mobile-based, self-reporting, observational survey among patients with asthma and CVA. The app was downloaded 7855 times between February 2016 and February 2018, and enabled collection of data on symptoms, comorbidities, quality of life, medications, asthma control, and adherence. Of the 1744 eligible participants (median age 33 years; range 20-74 years; male-to-female ratio 38.7:61.3), 50.97% (889/1744) reported unscheduled visits, 62.84% (1096/1744) reported regularly scheduled visits, 23.14% (402/1737) smoked, and 40.75% (705/1730) had pets. In addition, 91.89% (1598/1739) of participants had atopic predisposition, including allergic rhinitis and atopic dermatitis. Daily inhaled corticosteroid and oral corticosteroid treatment had been prescribed for 89.45% (1552/1735) and 22.07% (383/1735) of participants, respectively. Although an asthma control questionnaire demonstrated poor asthma control in 58.48% (1010/1727), a leukotriene receptor antagonist, theophylline, and a long-acting muscarinic antagonist had been prescribed for only 30.66% (532/1735), 15.91% (276/1735), and 4.38% (76/1735), respectively. The Adherence Starts with Knowledge 12 total score was 29. In the 421 participants who repeated the questionnaire, asthma control increased significantly between the initial and last rounds (P=.002). Users of this mHealth app in Japan had poorly controlled asthma and may need more treatment for asthma and their comorbidities. Repeated app users demonstrated improved asthma control. UMIN Clinical Trial Registry UMIN000021043; https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000023913.
Sections du résumé
BACKGROUND
Inappropriate asthma control reduces quality of life and causes increased exacerbations. Mobile health (mHealth) employs information and communication technology for surveying health-related issues.
OBJECTIVE
This noninterventional, observational study assessed current real-world asthma control levels among Japanese patients with asthma and cough variant asthma (CVA) using the Zensoku-Log app.
METHODS
We developed the app using the ResearchKit platform and conducted a mobile-based, self-reporting, observational survey among patients with asthma and CVA. The app was downloaded 7855 times between February 2016 and February 2018, and enabled collection of data on symptoms, comorbidities, quality of life, medications, asthma control, and adherence.
RESULTS
Of the 1744 eligible participants (median age 33 years; range 20-74 years; male-to-female ratio 38.7:61.3), 50.97% (889/1744) reported unscheduled visits, 62.84% (1096/1744) reported regularly scheduled visits, 23.14% (402/1737) smoked, and 40.75% (705/1730) had pets. In addition, 91.89% (1598/1739) of participants had atopic predisposition, including allergic rhinitis and atopic dermatitis. Daily inhaled corticosteroid and oral corticosteroid treatment had been prescribed for 89.45% (1552/1735) and 22.07% (383/1735) of participants, respectively. Although an asthma control questionnaire demonstrated poor asthma control in 58.48% (1010/1727), a leukotriene receptor antagonist, theophylline, and a long-acting muscarinic antagonist had been prescribed for only 30.66% (532/1735), 15.91% (276/1735), and 4.38% (76/1735), respectively. The Adherence Starts with Knowledge 12 total score was 29. In the 421 participants who repeated the questionnaire, asthma control increased significantly between the initial and last rounds (P=.002).
CONCLUSIONS
Users of this mHealth app in Japan had poorly controlled asthma and may need more treatment for asthma and their comorbidities. Repeated app users demonstrated improved asthma control.
TRIAL REGISTRATION
UMIN Clinical Trial Registry UMIN000021043; https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000023913.
Identifiants
pubmed: 32795993
pii: v22i8e19006
doi: 10.2196/19006
pmc: PMC7455863
doi:
Banques de données
UMIN-CTR
['UMIN000021043']
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e19006Informations de copyright
©Norihiro Harada, Sonoko Harada, Jun Ito, Ryo Atsuta, Satoshi Hori, Kazuhisa Takahashi. Originally published in the Journal of Medical Internet Research (http://www.jmir.org), 14.08.2020.
Références
Allergol Int. 2019 Apr;68(2):150-157
pubmed: 30648539
J R Soc Med. 2015 Aug;108(8):294-6
pubmed: 26268915
J Allergy Clin Immunol. 2004 Jan;113(1):59-65
pubmed: 14713908
JMIR Mhealth Uhealth. 2019 Apr 24;7(4):e13204
pubmed: 31017586
Allergol Int. 2017 Jul;66(3):411-417
pubmed: 27712949
Appl Clin Inform. 2017 Oct;8(4):1068-1081
pubmed: 29241254
Prim Care Respir J. 2009 Dec;18(4):300-5
pubmed: 19562233
Intern Med. 2018 Dec 1;57(23):3357-3363
pubmed: 30101909
Allergol Int. 2017 Apr;66(2):163-189
pubmed: 28196638
Nat Biotechnol. 2017 Apr;35(4):354-362
pubmed: 28288104
J Thorac Dis. 2017 Aug;9(8):2350-2359
pubmed: 28932539
J Allergy Clin Immunol Pract. 2018 Nov - Dec;6(6):1989-1998.e3
pubmed: 29627457
World Allergy Organ J. 2012 Apr;5(Suppl 3):S212-7
pubmed: 23268481
Clin Transl Allergy. 2018 Oct 25;8:45
pubmed: 30386555
N Engl J Med. 2015 Jan 29;372(5):456-63
pubmed: 25629743
J Asthma. 2019 Jun;56(6):632-641
pubmed: 29969920
JMIR Mhealth Uhealth. 2018 Sep 13;6(9):e177
pubmed: 30213779
Sci Data. 2016 Mar 03;3:160011
pubmed: 26938265
JMIR Mhealth Uhealth. 2017 Aug 02;5(8):e113
pubmed: 28768606
Eur Respir J. 2000 Nov;16(5):802-7
pubmed: 11153575
Ann Allergy Asthma Immunol. 2016 Dec;117(6):613-619
pubmed: 27979018
J Am Med Inform Assoc. 2018 Dec 1;25(12):1685-1695
pubmed: 30445467
BMC Health Serv Res. 2016 Oct 21;16(1):598
pubmed: 27769236
J Allergy Clin Immunol. 2006 Mar;117(3):549-56
pubmed: 16522452
Respirology. 2017 May;22(4):651-661
pubmed: 28328160
Arch Dis Child. 2018 Apr;103(4):392-397
pubmed: 28903951
Intern Med. 2019 Jan 15;58(2):175-185
pubmed: 30210101
Curr Med Res Opin. 2008 Nov;24(11):3197-206
pubmed: 18922213
J Am Med Inform Assoc. 2017 May 1;24(3):619-632
pubmed: 27694279
Ocul Surf. 2020 Apr;18(2):312-319
pubmed: 32113987
Acad Med. 2017 Feb;92(2):157-160
pubmed: 27119325
Arerugi. 2008 Feb;57(2):107-20
pubmed: 18349585
Lancet. 2018 Feb 24;391(10122):783-800
pubmed: 29273246
Sci Data. 2018 May 22;5:180096
pubmed: 29786695
JMIR Mhealth Uhealth. 2017 Dec 18;5(12):e190
pubmed: 29254914
J Med Internet Res. 2014 Feb 18;16(2):e51
pubmed: 24550161
JAMA Cardiol. 2017 Jan 1;2(1):67-76
pubmed: 27973671
Curr Med Res Opin. 2008 Jul;24(7):2127-38
pubmed: 18554431